International Journal of Hematology

, Volume 92, Issue 4, pp 579–586

Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka

  • Tsutomu Kobayashi
  • Junya Kuroda
  • Kazuho Shimura
  • Teruaki Akaogi
  • Eri Kawata
  • Miki Kiyota
  • Takashi Tanaka
  • Yuri Kamitsuji
  • Satoshi Murakami
  • Mayumi Hatsuse
  • Akira Okano
  • Toshiki Iwai
  • Satomi Ueda
  • Masahiko Koshida
  • Hitoji Uchiyama
  • Yosuke Matsumoto
  • Hiroto Kaneko
  • Nobuhiko Uoshima
  • Yutaka Ueda
  • Yutaka Kobayashi
  • Chihiro Shimazaki
  • Shigeo Horiike
  • Masafumi Taniwaki
Original Article

DOI: 10.1007/s12185-010-0696-4

Cite this article as:
Kobayashi, T., Kuroda, J., Shimura, K. et al. Int J Hematol (2010) 92: 579. doi:10.1007/s12185-010-0696-4

Abstract

We conducted a retrospective collaborative investigation of bortezomib (Bor) plus dexamethasone (Dex) therapy (BD Tx) for 88 relapsed or refractory (Rel/Ref) MM patients at six institutes. One cycle BD Tx comprised of Bor (1.3 mg/m2/day) on days 1, 4, 8 and 11, and Dex on days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days, and the mean number of BD Tx cycles was 3. The overall response rate was 66.9%, the median overall survival (OS) was 510 days, and the median progression-free survival (PFS) was 113 days. Attainment of partial response (PR) with the first course of BD Tx associated with the longer OS and PFS and late good responder, while no patient who did not achieve PR with the first cycle attained better than very good PR (VGPR) with the subsequent BD Tx. Patient age of less than 64 years old also associated with the longer OS and PFS. In addition, both an earlier disease stage and Dex dosage had a significant impact on OS, while the attainment of VGPR within 2 cycles had a significantly longer PFS. Earlier BD Tx courses may be predictive for the subsequent therapeutic pathway of Rel/Ref MM.

Keywords

BortezomibMultiple myelomaRelapse

Supplementary material

12185_2010_696_MOESM1_ESM.tif (99 kb)
Impact of the number of regimen prior to BD on OS and PFS for BD Tx. Kaplan-Meier plots of OS (a) and PFS (b) according to the number of prior regimens 1-2 (solid line), 3-5 (dotted line) and 6 or more (gray line) regimens (TIFF 98 kb)
12185_2010_696_MOESM2_ESM.tif (123 kb)
Supplementary material 2 (TIFF 122 kb)
12185_2010_696_MOESM3_ESM.tif (109 kb)
Supplementary material 3 (TIFF 108 kb)

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Tsutomu Kobayashi
    • 1
  • Junya Kuroda
    • 1
  • Kazuho Shimura
    • 1
    • 2
  • Teruaki Akaogi
    • 3
  • Eri Kawata
    • 3
  • Miki Kiyota
    • 1
    • 3
  • Takashi Tanaka
    • 3
  • Yuri Kamitsuji
    • 4
  • Satoshi Murakami
    • 5
  • Mayumi Hatsuse
    • 5
  • Akira Okano
    • 5
  • Toshiki Iwai
    • 6
  • Satomi Ueda
    • 6
  • Masahiko Koshida
    • 6
  • Hitoji Uchiyama
    • 1
  • Yosuke Matsumoto
    • 1
  • Hiroto Kaneko
    • 2
  • Nobuhiko Uoshima
    • 4
  • Yutaka Ueda
    • 6
  • Yutaka Kobayashi
    • 3
  • Chihiro Shimazaki
    • 5
  • Shigeo Horiike
    • 1
  • Masafumi Taniwaki
    • 1
  1. 1.Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Department of HematologyAiseikai Yamashina HospitalKyotoJapan
  3. 3.Department of HematologyKyoto Second Red Cross HospitalKyotoJapan
  4. 4.Department of HematologyMatsushita Memorial HospitalOsakaJapan
  5. 5.Department of HematologyKyoto Social Insurance HospitalKyotoJapan
  6. 6.Department of HematologyKyoto First Red Cross HospitalKyotoJapan